文献速递贫血与红细胞疾病血栓与止血

镰状细胞病患者出血风险的人群研究

Bleeding in patients with sickle cell disease: a population-based study.
PubMed 文献 · Blood Adv · 2020-01-01

该回顾性人群研究纳入1991至2014年6423例镰状细胞病患者,发现40岁时首次出血累积发生率为21%,60岁时增至41%,出血以胃肠道为主,且出血与死亡风险增加相关。

要点

  • 镰状细胞病患者40岁时首次出血累积发生率为21%,60岁时为41%。
  • 出血事件以胃肠道出血为主,占41.6%,尤其上消化道。
  • 出血与死亡风险增加相关,校正后HR为2.09。

核心结论

  • 镰状细胞病患者出血发生率较高,尤其上消化道出血,且出血与死亡风险增加独立相关。

研究设计与样本

  • 回顾性人群研究,利用加利福尼亚州急诊和住院数据库,纳入1991至2014年6423例镰状细胞病患者,采用Cox比例风险回归模型分析。

主要发现

  • 40岁时任何首次出血事件的累积发生率为21%(95%CI 19.8%-22.3%),60岁时增至41%(95%CI 38.8%-43.1%)。
  • 出血事件以胃肠道出血为主,占41.6%,尤其上消化道。
  • 出血风险增加与住院频率增加(HR 2.16;95%CI 1.93-2.42)、出血前180天静脉血栓栓塞(HR 4.24;95%CI 2.86-6.28)、股骨头坏死(HR 1.25;95%CI 1.08-1.46)和缺血性卒中(HR 1.65;95%CI 1.20-2.26)相关。
  • 出血与死亡风险增加两倍相关(HR 2.09;95%CI 1.82-2.41),校正其他镰状细胞病相关并发症后。

临床怎么用

  • 临床应关注镰状细胞病患者的出血风险,尤其有频繁住院、静脉血栓栓塞、股骨头坏死或缺血性卒中病史者,并警惕上消化道出血。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bleeding is a known complication of sickle cell disease (SCD) and includes hemorrhagic stroke, hematuria, and vitreous hemorrhage. However, the incidence of bleeding events in patients with SCD has not been well described. We present a retrospective, population-based study examining the cumulative incidence of bleeding in 6423 patients with SCD from 1991 to 2014. We also studied risk factors associated with bleeding and the effects of bleeding on mortality, using Cox proportional hazards regression models. We used California emergency department and hospitalization databases to identify patients with SCD with intracranial hemorrhage, gastrointestinal (GI) bleeding, hemophthalmos, gross hematuria, epistaxis, menorrhagia, and other bleeding events. The cumulative incidence of any first bleeding event at age 40 years was 21% (95% confidence interval [CI], 19.8%-22.3%), increasing with age to 41% by age 60 years (95% CI, 38.8%-43.1%). The majority of bleeding events were GI (41.6%), particularly from the upper GI tract. A higher bleeding risk was associated with increased frequency of hospitalization (hazard ratio [HR], 2.16; 95% CI, 1.93-2.42), venous thromboembolism 180 days before bleeding event (HR, 4.24; 95% CI, 2.86-6.28), osteonecrosis of the femoral head (HR, 1.25; 95% CI, 1.08-1.46), and ischemic stroke (HR, 1.65; 95% CI, 1.20-2.26). Bleeding was also associated with a twofold increased risk for death (HR, 2.09; 95% CI, 1.82-2.41) adjusted for other SCD-related complications. Our novel finding of a high incidence of bleeding in patients with SCD, particularly from the upper GI tract, suggests that patients with SCD may be predisposed to bleeding, with possible etiologies including increased use of nonsteroidal anti-inflammatory drugs, mucosal infarction from vascular occlusion by sickled red blood cells, and increased stress ulceration from frequent hospitalization.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hariharan N, Brunson A, Mahajan A, et al. Bleeding in patients with sickle cell disease: a population-based study. Blood Adv. 2020. PMID: 32108229. doi:10.1182/bloodadvances.2019000940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。